Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares

Bulletin Express

04/08

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.

The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.

Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1161871922"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161871922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161871922?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161871922","market":"hk","top_or_hot":-1,"title":"Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares","media":"Bulletin Express","content":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1161871922","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161871922","pubTimestamp":1775654495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"科伦生物（SKB BIO-B）获得港交所批准H股全流通，转换821万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.\nThe newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.\nKelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}